Quick Answer
C4 Therapeutics, Inc. reported Total Revenue of $35.95 million for the year ending 2025.
- C4 Therapeutics, Inc. showed an increase of +1.0% in Total Revenue from 2024 to 2025.
- This data is from C4 Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $9.78 million | Q3 2021: $8.50 million | Q1 2022: $7.65 million | Q2 2022: $13.83 million | Q3 2022: $6.75 million | Q1 2023: $3.76 million | Q2 2023: $2.66 million | Q3 2023: $11.07 million | Q1 2024: $3.04 million | Q2 2024: $12.01 million | Q3 2024: $15.36 million | Q1 2025: $7.24 million | Q2 2025: $6.46 million | Q3 2025: $11.23 million.
- Over the full 5 years of available data (2021 to 2025), C4 Therapeutics, Inc.'s Total Revenue has declined by 21.5%.
- Historical annual values: Fiscal year 2025: $35.95 million | Fiscal year 2024: $35.58 million | Fiscal year 2023: $20.76 million | Fiscal year 2022: $31.10 million | Fiscal year 2021: $45.79 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: